期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性骨髓瘤伴肾功能损害的临床特征和疗效分析 被引量：1

Clinical characteristics of multiple myeloma with renal impairment and the efficacy of different treatments
原文传递
导出
摘要 多发性骨髓瘤（multiple myeloma,MM）是最常见的血液肿瘤之一,为浆细胞恶性克隆性疾病,30％～40％的患者出现肾功能损害（Renal Impairment,RI）.RI被认为和患者的预后相关,用传统化疗,RI患者的生存期一般小于2年.我们对66例MM伴RI患者进行回顾性分析,旨在更多了解该类患者的临床特征,以及评价新型药物和传统化疗对患者的RI和MM本病的疗效.
作者 刘彦 克晓燕 王晶 王艳芳 万文丽 张巍
机构地区 北京大学第三医院血液科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第9期842-844,共3页 Chinese Journal of Hematology
关键词 多发性骨髓瘤 肾功能损害 疗效分析 临床特征 恶性克隆性疾病 血液肿瘤 预后相关 患者
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Knudsen LM,Hjorth M,Hippe E.Renal failure in multiple myeloma:reversibility and impact on the prognosis.Nordic Myeloma Study Group[J].Eur J Haematol,2000,65 (3):175-181.
  • 2Kyle RA,Gertz MA,Witzig TE,et al.Review of 1027 patients with newly diagnosed multiple myeloma[J].Mayo Clin Proc,2003,78(1):21-33.
  • 3Augustson BM,Begum G,Dunn JA,et al.Early mortality after diagnosis of multiple myeloma:analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party[J].J Clin Oncol,2005,23 (36):9219-9226.
  • 4Levey AS,Coresh J,Balk E,et al.National Kidney Foundation practice guidelines for chronic kidney disease:evaluation,classification,and stratification[J].Ann Intern Med,2003,139 (2):137-147.
  • 5Ludwig H,Adam Z,Hajek R,et al.Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicindexamethasone in multiple myeloma:results of a phase Ⅱ study[J].J Clin Oncol,2010,28(30):4635-4641.
  • 6Alexanian R,Barlogie B,Dixon D.Renal failure in multiple myeloma.Pathogenesis and prognostic implications[J].Arch Intern Med,1990,150(8):1693-1695.
  • 7徐燕,安刚,邓书会,隋伟薇,冯晓燕,李菲,郝牧,王亚非,邱录贵.以硼替佐米为基础方案治疗56例伴肾功能损害的多发性骨髓瘤患者疗效分析[J].中华血液学杂志,2013,34(4):304-308. 被引量：11
  • 8Roussou M,Kastritis E,Christoulas D,et al.Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents[J].Leuk Res,2010,34 (10):1395-1397.
  • 9Dimopoulos MA,Roussou M,Gkotzamanidou M,et al.The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma[J].Leukemia,2013,27(2):423-429.
  • 10Heher EC,Goes NB,Spitzer TR,et al.Kidney disease associated with plasma cell dyscrasias[J].Blood,2010,116(9):1397-1404.

二级参考文献20

  • 1袁振刚,侯健,周帆,王东星,付卫军,陈玉宝,奚昊,杨盛玲.硼替佐米联合地塞米松治疗16例复发、难治性多发性骨髓瘤患者[J].中华血液学杂志,2006,27(10):653-655. 被引量：21
  • 2Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 2003, 78 : 21-33.
  • 3Kleber M, Ihorst G, Deschler B, et al. Detection of renal impair- ment as one specific comorbidity factor in multiple myeloma: mui- r/center study in 198 consecutive patients. EurJ Haematol, 2009, 83 : 519-527.
  • 4Dimopoulos MA, Roussou M, Gavriatopoulou M, eta]. Reversi- bility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive fac- tors. Clin Lymphoma Myeloma, 2009, 9:302-306.
  • 5Ludwig H, Drach J, Graf H, et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myelo- ma. Haematologica, 2007, 92 : 1411-1414.
  • 6Dimopoulos MA, Richardson PG, Schlag R, et al. VMP (Borte-zomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with muhiple myeloma with moderately impaired renal function, and results in reversal of renal impair- merit : Cohort analysis of the phase III VISTA study. J Clin Oncol, 2009, 27 : 6086-6093.
  • 7Uttamsingh V, Lu C, Miwa G, et al. Relative contributions of the five major human cytochromes P450, 1A2, 2C9,2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor borte- zomib. Drug Metab Dispos, 2005, 33:1723-1728.
  • 8Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia, 2009, 23: 3-9.
  • 9Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol, 2005, 23: 3412- 3420.
  • 10Piro E, Molica S. A systematic review on the use of borezomib in multiple myeloma patients with renal impairment: what is the published evidence? Acta Haematol, 2011, 126: 163-168.

共引文献10

同被引文献15

  • 1Lee SE, Kim JH, Jeon YW, et al. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma [J]. Ann Hematol, 2015, 94 (3): 445-452. doi: 10.1007/s00277-014- 2216-8.
  • 2Lu J, Lu J, Chen W, et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis [J]. Blood Cancer J, 2014, 4: e239. doi: 10.1038/bcj.2014.55.
  • 3Vagnoni D, Travaglini F, Pezzoni V, et al. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics [J]. Br J Haematol, 2015, 170 (4): 523-531. doi: 10.1111/bjh.13484.
  • 4Gonsalves WI, Morice WG, Rajkumar V, et al. Quantification of clonal circulating plasma cells in relapsed multiple myeloma [ J ]. Br J Haematol, 2014, 167(4): 500-505. doi: 10.11 ll/bjh.13067.
  • 5International Myeloma Working Group. Criteria for the classifi- cation of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group[J]. Br J Haematol, 2003, 121 (5): 749-757.
  • 6Kumar S, Kimlinger T, Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders [J]. Best Pract Res Clin Haematol, 2010, 23 (3): 433-451. doi: 10.1016/j. beha.2010.09.002.
  • 7Paiva B, Almeida J, Ptrez- Andrts M, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders [ J]. Cytometry B Clin Cytom, 2010, 78(4): 239-252. doi: 10.1002/cyto.b.20512.
  • 8Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders [J]. Haematologica, 2008, 93(3): 431-438. doi: 10.3324/haematol.11080.
  • 9Cannizzo E, Carulli G, Del Vecchio L, et al. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytome- try: a new statistical model[J]. Am J Clin Pathol, 2012, 137(3): 377-386. doi: 10.1309/.
  • 10AJCP63TOCFNAMDMS. Thiele B, Kloster M, Alawi M, et al. Next-generation sequenc- ing of peripheral B-lineage cells pinpoints the circulating clono- typic cell pool in multiple myeloma [J]. Blood, 2014, 123 (23): 3618-3621. doi: 10.1182/blood-2014-02-556746.

引证文献1

二级引证文献3

中华血液学杂志
2014年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部